These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 10165313)
1. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients. Brennan DC; Schnitzler MA; Baty JD; Ceriotti CS; Lowell JA; Shenoy S; Howard TK; Woodward RS Pharmacoeconomics; 1997 Mar; 11(3):237-45. PubMed ID: 10165313 [TBL] [Abstract][Full Text] [Related]
2. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Wilde MI; Goa KL Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551 [TBL] [Abstract][Full Text] [Related]
3. Muromonab-CD3 and antithymocyte globulin in renal transplantation. Burk ML; Matuszewski KA Ann Pharmacother; 1997 Nov; 31(11):1370-7. PubMed ID: 9391693 [TBL] [Abstract][Full Text] [Related]
4. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants. Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094 [TBL] [Abstract][Full Text] [Related]
7. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol. Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247 [TBL] [Abstract][Full Text] [Related]
8. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study. Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990 [TBL] [Abstract][Full Text] [Related]
9. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era. Hariharan S; Alexander JW; Schroeder TJ; First MR Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516 [TBL] [Abstract][Full Text] [Related]
10. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Cole EH; Cattran DC; Farewell VT; Aprile M; Bear RA; Pei YP; Fenton SS; Tober JA; Cardella CJ Transplantation; 1994 Jan; 57(1):60-7. PubMed ID: 8291115 [TBL] [Abstract][Full Text] [Related]
11. Basiliximab: a review of its use as induction therapy in renal transplantation. Chapman TM; Keating GM Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658 [TBL] [Abstract][Full Text] [Related]
12. Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients. Marfo K; Akalin E; Wang C; Lu A Am J Health Syst Pharm; 2011 Dec; 68(23):2276-82. PubMed ID: 22095818 [TBL] [Abstract][Full Text] [Related]
13. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect. Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580 [TBL] [Abstract][Full Text] [Related]
14. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin. Wang W; Yin H; Li XB; Hu XP; Yang XY; Liu H; Ren L; Wang Y; Zhang XD Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543 [TBL] [Abstract][Full Text] [Related]
15. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death. Peng W; Liu G; Xie W; Huang H; Wu J; Shou Z; Chen J Int J Clin Pract Suppl; 2015 May; (183):23-8. PubMed ID: 26177071 [TBL] [Abstract][Full Text] [Related]
17. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation. Kitabayashi K; Munn SR; Sterioff S Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964 [No Abstract] [Full Text] [Related]
18. Induction therapy with antithymocyte globulin reduces the incidence of allograft rejection and improves graft survival in cadaver renal transplantation. Abouna GM; Kumar MS; Stephan R; Prior JE; Lyons P; Bulova SI; al-Abdullah IH Transplant Proc; 1993 Jun; 25(3):2241-2. PubMed ID: 8516886 [No Abstract] [Full Text] [Related]
19. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Lü TM; Yang SL; Wu WZ; Tan JM Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554 [TBL] [Abstract][Full Text] [Related]
20. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]